Who are Repertoire Immune Medicines's investors?

Repertoire Immune Medicines's investors include Flagship Pioneering, SoftBank Vision Fund, JDRF T1D Fund.

Repertoire Immune Medicines

Founded 2020 · 84 employees on LinkedIn · 3 known investors

Find your way into Repertoire Immune Medicines

318 people in our graph share verified history with the Repertoire Immune Medicines team — schools, employers, funds. One of them is your warm intro.

Lori Goughunlockedknows John Delyani · together at Tmunity Therapeutics Incorporated (overlapped)

knows the team · via Tmunity Therapeutics Incorporated

×2knows the team · via Ciba-Geigy

×3knows the team · via Pandion Therapeutics

×2knows the team · via Repertoire Immune Medicines

×3knows the team · via Pharmacia

Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.

AI & Machine Learning Biotech Deep Tech Digital Health Healthtech

Founders & leadership

Torben Straight NissenChief Executive OfficerExecutive Officer, Director at Rubius Therapeutics

Anthony Coyle President, Research and DevelopmentDr. Anthony Coyle is President of Research and Development at Repertoire Immune Medicines and formerly founded Pandion Therapeutics, a biotech company developing autoimmune therapies that raised $58 million in Series A funding. He has held leadership positions in drug discovery at Pfizer, MedImmune/AstraZeneca, Millennium Pharmaceuticals, and the Glaxo Institute, with expertise spanning immunology, inflammation research, and translating early-stage science into clinical programs; he holds a first-class honors degree from King's College, University of London, and has authored over 200 peer-reviewed publications.

Robert AndtbackaChief Medical Officer

John Delyani Chief Business OfficerJohn Delyani holds a PhD and MBA and brings two decades of operational experience in corporate strategy, business development, and corporate development across biotech and pharmaceutical companies. He has led execution of over 40 business agreements and serves as Chief Business Officer of Repertoire Immune Medicines.

Jan KisielowChief Scientific Officer, Repertoire Immune Medicines (Switzerland) Ltd.

Investors · 3

Flagship Pioneeringlisted by Flagship PioneeringCambridge · $500K – $10M

How we know: Flagship Pioneering's portfolio page · a partner's Signal profile · Not right? Tell us

SoftBank Vision Fundlisted by SoftBank Vision FundLondon

JDRF T1D FundreportedBoston

How we know: funding news · press coverage · Not right? Tell us

Founder mafia

4 people who came through Repertoire Immune Medicines went on to found or lead other companies.

Noubar AfeyanBoard Member and Co-FounderFounded ProFound Therapeutics +15 Lovisa AfzeliusSenior Vice PresidentFounded AllTrna +3 John G. CoxChief Executive Officer Repertoire Immune MedicinesFounded Torque Therapeutics +1 Anthony CoylePresident, Research and DevelopmentFounded Pandion Therapeutics

Frequently asked questions

What does Repertoire Immune Medicines do?: Repertoire's Decode platform focuses on mapping the immune synapse — the interactions between T cell receptors, epitopes, and HLA molecules — to support the development of medicines targeting cancer and other diseases. It operates in immunology-based drug discovery and therapeutics.
Who are Repertoire Immune Medicines's investors?: Repertoire Immune Medicines's investors include Flagship Pioneering, SoftBank Vision Fund, JDRF T1D Fund.